Trial Information

Summary: A Study of Kytril (Granisetron) in the Prevention of Post-Operative Nausea and Vomiting (PONV) in Pediatric Subjects Undergoing Tonsillectomy or Adenotonsillectomy

Status: No longer recruiting

Protocol Number: ML16633

Sponsor: Hoffmann-La Roche

Company Division: Pharmaceutical

Official Scientific Title: A randomized, double-blind study of 2 dose levels of Kytril on the prevention of post-operative nausea and vomiting in pediatric patients undergoing surgery with general anesthesia

Brief Summary: This 2 arm study will evaluate the efficacy and safety of a single intravenous injection of Kytril in preventing PONV in children. Patients will be randomized to receive a single dose of either 20 micrograms or 40 micrograms Kytril iv 15 minutes prior to the end of surgery with general anesthesia for tonsillectomy or adenotonsillectomy. The anticipated time on study treatment is <3 months, and the target sample size is 100-500 individuals. Target sample size is 171.

Study Phase: IV

Study Design / Study Details:

  • Purpose: Treatment
  • Allocation: Non-Randomized
  • Masking: Open Label
  • Control: Uncontrolled
  • Assignment: Parallel
  • Endpoints: Safety/Efficacy

Study Type:

Interventional

Condition: Post-Operative Nausea and Vomiting

Intervention Type: Drug

Intervention Name: granisetron [Kytril]

Primary Outcome: 1. Percentage of patients with no vomiting Time frame: 0-2h after end of surgery (time of extubation)

Key Secondary Outcomes: 1. Percentage of patients with no vomiting Time frame: 0-24h after time of extubation 2. Time to first vomiting episode Time frame: Event driven 3. Adverse experiences Time frame: Throughout study

Inclusion Criteria:

  • males and females 2-16 years of age
  • scheduled to undergo elective surgery for tonsillectomy or adenotonsillectomy requiring general anesthesia and endotracheal intubation
  • scheduled for hospital admission for no longer than 24 hours

Exclusion Criteria:

  • known allergy or other contraindication to the use of Kytril or any of its components
  • known allergy to any other 5HT3 antagonist
  • history of motion sickness or post-operative nausea or vomiting
  • nausea or vomiting in the 24 hours prior to anesthesia

Gender: Males or Females

Age Limits: Min: 2 Years Max: 16 Years

Accepts Healthy Volunteers: No

Anticipated Start Date: April, 2007

Trial Registration Date: 08/31/2005

Date Last Updated: 09/19/2008

Link To Trial Results

Contact:

Research Site:
Located In:
Dallas, TX 75390
Telephone: 973-235-5000 or 800-526-6367

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: October 6, 2008 at 2:50:22 PM


Back to Centerwatch Trial Listing by Location


Additional resources
in this illness area

Copyright © 1995 - 2008, CenterWatch
All Rights Reserved

This site was developed in association with Illumina Interactive, Boston, MA